Tags Archive Navigation
icon
-
Media ReleaseNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
-
Media ReleaseNovartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
-
Media ReleaseNovartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition